– Conference Call and Webcast to Follow at 5:00 p.m. EST/ 2:00 p.m.
PST –
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 29, 2019--
Exelixis,
Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full
year 2018 financial results will be released on Tuesday, February 12,
2019 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis
management will host a conference call and webcast to discuss the
results and provide a general business update. Access to the event is
available via the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the conference call to ensure adequate time
for any software download that may be required to listen to the webcast.
Alternatively, please call 855-793-2457 (domestic) or 631-485-4921
(international) and provide the conference call passcode 6681209 to join
by phone.
A telephone replay will be available until 8:00 p.m. EST on February 14,
2019. Access numbers for the telephone replay are: 855-859-2056
(domestic) and 404-537-3406 (international); the passcode is 6681209. A
webcast replay will also be archived on www.exelixis.com
for one year.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. Our discovery efforts
have resulted in four commercially available products, CABOMETYX®
(cabozantinib), COMETRIQ® (cabozantinib), COTELLIC®
(cobimetinib) and MINNEBRO™ (esaxerenone), and we have entered into
partnerships with leading pharmaceutical companies to bring these
important medicines to patients worldwide. Supported by revenues from
our marketed products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our pipeline.
We are supplementing our existing therapeutic assets with targeted
business development activities and internal drug discovery – all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis is a member of Standard &
Poor’s (S&P) MidCap 400 index, which measures the performance of
profitable mid-sized companies. For more information about Exelixis,
please visit www.exelixis.com,
follow @ExelixisInc on
Twitter or like Exelixis,
Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are
registered U.S. trademarks. MINNEBRO is a Japanese trademark.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190129005880/en/
Source: Exelixis, Inc.
Susan Hubbard
Executive Vice President,
Public
Affairs & Investor Relations
Exelixis, Inc.
650-837-8194
shubbard@exelixis.com
